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Abstract
Background: Interleukin 6 (IL-6) has been related to beta-amyloid aggregation and the appearance of
hyperphosphorylated tau in Alzheimer’s disease (AD) brain. However, previous studies relating IL-6 genetic
polymorphisms to AD included few and unrepresentative single nucleotide polymorphisms (SNPs) and the results
were inconsistent.
Methods: This is a case-control study. A total of 266 patients with AD, aged≧65, were recruited from three
hospitals in Taiwan (2007-2010). Controls (n = 444) were recruited from routine health checkups and volunteers of
the hospital during the same period of time. Three common IL-6 haplotype-tagging SNPs were selected to assess
the association between IL-6 polymorphisms and the risk of late-onset AD (LOAD).
Results: Variant carriers of IL-6 rs1800796 and rs1524107 were significantly associated with a reduced risk of LOAD
[(GG + GC vs. CC): adjusted odds ratio (AOR) = 0.64 and (CC + CT vs. TT): AOR = 0.60, respectively]. Haplotype CAT
was associated with a decreased risk of LOAD (0 and 1 copy vs. 2 copies: AOR = 0.65, 95% CI = 0.44-0.95). These
associations remained significant in ApoE e4 non-carriers only. Hypertension significantly modified the association
between rs2069837 polymorphisms and the risk of LOAD (pinteraction = 0.03).
Conclusions: IL-6 polymorphisms are associated with reduced risk of LOAD, especially in ApoE e4 non-carriers. This
study identified genetic markers for predicting LOAD in ApoE e4 non-carriers.
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Background
Dementia is a neurodegenerative disease characterized
by decline or loss in cognitive function. Alzheimer’s dis-
ease (AD) is the most common cause of dementia. In
the United States in 2006, AD was the fifth leading
cause of death in the elderly (age 65 or older) [1]. In
Taiwan, the prevalence of dementia is around 1.7-4.3%
among the elderly [2] and the number of dementia
patients keeps increasing. Therefore, dementia has
become an important health issue in aging populations.
Interleukin-6 (IL-6), an inflammatory cytokine, plays
an important role in the development and differentiation
of neurons in both peripheral and central nervous sys-
tem [3]. IL-6 promotes the activation of microglia [4]
and then induces the synthesis of acute phase proteins
[5] and phosphorylation of tau protein in neurons [6].
In AD brain, microglia and astrocytes are stimulated by
IL-6 and are recruited to release proinflammatory cyto-
kines and acute-phase proteins, such as C-reactive pro-
tein (CRP) [7]. Therefore, IL-6 plays a pivotal role in
brain inflammation that maybe important in AD
pathogenesis.
Previous studies relating IL-6 polymorphisms to AD
risk have been inconsistent. A Caucasian study found
that the CC genotype of IL-6 promoter SNP rs1800795
was significantly associated with an increased risk for
AD [8]. However, this association has not been observed
in other Caucasian studies [9-11]. In addition, the GG
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ciated with a decreased risk for AD in two Chinese
populations [12,13]. For the latter study [13], a signifi-
cant association was observed only for Apolipoprotein E
(ApoE) e4 carriers. In contrast, no significant association
was observed in a Japanese population [14]. Further-
more, the variant rs13447446 was very rare in a Korean
study [minor allele frequency (MAF) = 0.006] [15] and a
Chinese study (MAF = 0) [12] and thus no association
analysis was performed. In summary, previous studies
(see Table 1) have been inconsistent in relating IL-6
polymorphisms to AD risk. This may be attributable to
different ethnic groups, SNPs selected, study period, or
sample size.
IL-6 plays an important role in inflammation. Past stu-
dies relating IL-6 polymorphisms to AD risk have been
limited to few and unrepresentative SNPs in IL-6.S o m e
SNPs (e.g., rs13447446) even showed no variations in
Asians. Therefore, this study used a systematic approach
to select haplotype-tagging SNPs (htSNPs) in IL-6 to
explore their association with AD risk. Because ApoE e4
status and some vascular risk factors [e.g., hypertension,
hyperlipidemia, and type 2 diabetes mellitus (DM)] may
affect the pathogenesis of dementia [16-18], this study
further explored the effect of modification by these factors.
Methods
Study population
This was a case-control study. A total of 294 late-onset
AD (LOAD) cases were recruited from the neurology
clinics of three teaching hospitals in northern Taiwan
from 2007 to 2010. Healthy controls (n = 503) were
recruited from elderly health checkup and volunteers of
the hospital during the same period of time. All partici-
pants were Taiwanese aged 65 years or older. Partici-
pants with a history of depression, dementia subtypes
other than AD, Parkinson’s disease, hemorrhagic stroke,
cerebral infarction, or organic brain tumors were
excluded. After further exclusion of participants without
blood samples, a total of 266 LOAD and 444 controls
were included for data analyses. The study protocol has
been approved by the Institutional Review Boards of
National Taiwan University Hospital, En Chu Kong
Hospital, and Cardinal Tien’s Hospital. Written
informed consent was obtained from each study partici-
pant. The consent from the legal guardian/next of kin
was obtained when patientsh a ds e r i o u sc o g n i t i v e
impairment. A self-reported questionnaire was adminis-
tered to collect information on demography, comorbid-
ity (e.g., hypertension, hyperlipidemia, and type 2 DM),
and lifestyle.
Table 1 Previous studies relating IL-6 polymorphisms to AD risk
Reference Population
(AD:control)
SNP (w.t./variant)
a
Haplotype (SNP)
Results Limitations
Arosio et al.
Neurobiol. Aging 2004,
25:1009-15 [9]
Italian
(65:65)
rs1800795 (G/C) No significant association ◈Italian only
◈One SNP only
◈Small sample size
Licastro et al.
Neurobiol. Aging
2003, 24:921-26 [8]
Italian
(332:393)
rs1800795 (G/C) rs1800795:
CC vs. GG: OR = 1.62, 95% CI =
1.20-2.17
◈Italian only
◈One SNP only
Depboylu et al.
Geriatr. Cogn. Disord
2004, 17:170-73 [10]
German
(113:108)
rs1800795 (G/C) No significant association ◈German only
◈One SNP only
van Oijen et al.
Neurosci. Lett.
2006, 402:113-17 [11]
Netherlander
(483:5636)
rs1800795 (G/C) No significant association ◈Netherlanders only
◈One SNP only
He et al.
Neurol. Sci.
2010, 31:165-8 [12]
Chinese
(318:324)
rs1800796 (C/G)
rs13447446 (G/C)
rs1800796:
GG vs. CC: OR = 0.42, 95% CI =
0.20-0.89
◈Chinese only
◈Not applicable for rs13447446 (No GC
or CC variants)
Wang et al.
Neurosci. Lett.
2010, 482:260-3 [13]
Chinese
(341:421)
rs1800796 (C/G)
rs7802308 (A/T)
haplotype rs1800796/
rs7802308
rs1800796 (in ApoE e4 carrier):
1) CC vs. CG + GG: OR = 3.3,
95% CI = 1.64-6.67
2) A risk haplotype (CA) (OR =
2.24)
3) A protective haplotype (GA)
(OR = 0.41)
◈Chinese only
◈Significant only in ApoE e4-carrier
◈rs7802308 is a rare SNP for analysis
Nishimura et al.
Neurosci. Lett.
2004, 368:140-3 [14]
Japanese
(172:163)
rs1800796 (C/G) No significant association ◈Japanese only
◈One SNP only
a Words underlined indicates SNPs genotyped in our study.
Abbreviations: OR, odds ratio; AD, Alzheimer’s disease; SNP, single nucleotide polymorphism; w.t., wild type.
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At each hospital, potential dementia cases were diag-
nosed by a neurologist. The Mini-Mental State Exami-
nation (MMSE) was used to evaluate participants with
cognitive impairment. The diagnosis of probable demen-
tia was evaluated using Diagnostic and Statistical Man-
ual of Mental Disorders (Fourth Edition) [19] criteria.
Head magnetic resonance imaging and computed tomo-
graphy were taken to exclude participants with organic
lesions. National Institute of Neurological and Commu-
nicative Disorders and Stroke and the Alzheimer’sD i s -
ease and Related Disorders Association (NINCDS-
ADRDA) Alzheimer’s Criteria [20] was used to diagnose
probable AD. The cognitive function of controls was
assessed by using Short Portable Mental Status Ques-
tionnaire [21] to exclude participants with possible
dementia and other mental disorders.
SNP selection and genotyping assay
Genotype data of common (frequency ≥ 5%) IL-6 SNPs
were downloaded from the International HapMap Pro-
ject (http://hapmap.ncbi.nlm.nih.gov) for Han Chinese
in Beijing, China (CHB). Haploview (http://www.broad-
institute.org/haploview/haploview) was used to define
haplotype block by using the modified Gabriel algorithm
[22,23]. Two htSNPs were selected among four common
SNPs using tagSNP program [24]. For comparison pur-
pose, SNP rs1800796 was further included because it
has been related to AD risk [12,13].
Blood samples were collected in tubes containing
sodium EDTA from each participant for genotyping.
After centrifugation, genomic DNA was extracted from
buffy coats using a QuickGene-Mini80 system (Fujifilm,
Tokyo, Japan) and then stored in a -80°C freezer. Geno-
types of ApoE SNPs were determined using the assay
developed by Chapman et al. [25]. Genotypes of IL-6
htSNPs were determined by Taqman Assay (Applied
Biosystems Inc., CA, USA) with genotyping success rate
greater than 95%. Five percent of internal samples were
selected and replicated for quality control, and the con-
cordance rate was 100%.
Statistical analysis
The distributions of demographic characteristics
between cases and controls were compared using Stu-
dent’s t-test for normally distributed continuous vari-
ables and a chi-square test for categorical variables. The
Hardy-Weinberg equilibrium (HWE) test was performed
among controls to examine possible genotyping error
and selection bias for each SNP. The ApoE diplotypes
(e2/e2, e2/e3, e3/e3, e2/e4, e3/e4,a n de4/e4) were deter-
mined by ApoE112 (rs429358)a n dApoE158 (rs7412)
[26]. ApoE e4 carriers were defined as participants carry-
ing e2/e4, e3/e4,o re4/e4 diplotypes; participants
carrying other diplotypes (e2/e2, e2/e3,a n de3/e3), were
defined as ApoE e4 non-carriers. The expectation-maxi-
mization algorithm was utilized to estimate haplotype
frequencies. Logistic regression models were performed
to estimate SNP- and haplotype-specific odds ratios
(OR) and 95% confidence intervals (CI) for LOAD
adjusting for age, gender, education, and ApoE e4 status.
Type I errors were controlled by using false discovery
rate (FDR) [27].
A likelihood ratio test was used to evaluate how ApoE
e4 status and vascular risk factors (e.g., type 2 DM,
hypertension, and hyperlipidemia) modified the associa-
tion between IL-6 polymorphisms and risk of LOAD.
Stratified analyses were performed subsequently to
assess the association between IL-6 polymorphisms and
risk of LOAD by these vascular risk factors. SAS version
9.2 (SAS Institute, Cary, NC) was used for statistical
analyses and all statistical tests were two-sided.
Results
Characteristics of the study population
This study included 266 incident LOAD cases and 444
controls. Compared with controls, LOAD cases were
older (79.8 vs. 73.1 years old), included more females
(64% vs. 52%), had a lower education level (≤ 6y e a r s :
50% vs. 11%), and included fewer with hypertension his-
tory (38% vs. 54%) or hyperlipidemia (18% vs. 30%), and
more ApoE e4 carriers (39% vs. 15%, Table 2). The dis-
tributions of body mass index (BMI), cigarette smoking,
alcohol consumption, and type 2 DM were similar
between LOAD cases and controls.
Table 2 Characteristics of the study population
Variables AD
N = 266
Control
N = 444
Age (mean ± SD) 79.8 ± 7.9* 73.1 ± 7.1
Female (%) 170 (64)* 233 (52)
Education (%)
≦6 years 134 (50)* 54 (11)
6-12 years 90 (34) 177 (40)
> 12 years 39 (15) 214 (48)
BMI at age 40s, kg/m
2(mean ± SD) 22.6 ± 3.1 22.4 ± 2.8
Cigarette smoking (%) 62 (23) 77 (17)
Alcohol consumption (%) 32 (12) 50 (11)
Type 2 DM (%) 48 (17) 62 (13)
Hypertension (%) 101 (38)* 239 (54)
Hyperlipidemia (%) 49 (18)* 135 (30)
ApoE e4 carriers (%) 104 (39)* 66 (15)
* p value < 0.05 was obtained by comparing AD and controls.
Abbreviations: AD, Alzheimer’s disease; BMI, body mass index; DM, diabetes
mellitus; ApoE e4, apolipoprotein E e4.
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Neither of the two ApoE SNPs (rs429358 and rs7412)
was out of HWE (Table 3). AopE rs429358 (ApoE112) is
a common SNP in this Chinese population (MAF = 0.08
in controls) and in Caucasians (MAF = 0.15, dbSNP
dataset). In contrast, HapMap data showed that
rs429358 is a rare variant in Chinese (CHB, MAF = 0)
and Japanese (JPN, MAF = 0.01). The MAF is similar
for ApoE rs7412 (ApoE158) across ethnic groups: Chi-
nese (HapMap CHB: 0.11; controls of this study: 0.08),
Caucasian (dbSNP: 0.08), and Japanese (HapMap: 0.05).
IL-6 SNPs and AD risk
Three IL-6 SNPs (rs1800796, rs2069837, and rs1524107)
were genotyped. The MAFs of these SNPs among con-
trols ranged from 0.19 to 0.27, which were similar to
t h eM A F s( 0 . 2 0 - 0 . 2 5 )o fC H Bg e n o t y p ed a t af r o mt h e
International HapMap Project (Table 3). In contrast,
M A Fo ft h e s et h r e eI L - 6S N P sw e r el o w e ri nJ a p a n e s e
(0.12, 0.10 and 0.18) and in Caucasians (0.04, 0.08, and
0.05) based on HapMap data. All IL-6 SNPs were in
HWE among controls. For each SNP, the genotype fre-
quencies were similar between cases and controls (data
not shown).
Participants carrying one or two copies of variant
SNP1 (rs1800796) or SNP3 (rs1524107) had a signifi-
cantly decreased risk of LOAD [SNP1: adjusted OR
(AOR) = 0.64, 95% CI = 0.43-0.94; SNP3: AOR = 0.60,
95% CI = 0.41-0.89] compared with those carrying 0
copies. These results remained significant after control-
l i n gf o rF D Ru n d e rd o m i n a n to ra d d i t i v em o d e l( T a b l e
4). After stratification by ApoE e4 status, SNP1 and
SNP3 were significantly associated with decreased
LOAD risk among ApoE e4 non-carriers (SNP1: AOR =
0.56, 95% CI = 0.35-0.90; SNP3: AOR = 0.55, 95% CI =
0.35-0.88, Table 4). These results remained statistically
significant after controlling for FDR (Table 4). In con-
trast, results were not significant among ApoE e4
carriers.
IL-6 haplotypes and AD risk
Three common (frequency ≥ 5%) htSNPs spanning IL-6
formed one haplotype block, which was determined by
the modified Gabriel et al. algorithm [22,23] (Figure 1).
Three common haplotypes (CAT, GGC, and GAC) with
a cumulative frequency of 99% in controls were identi-
fied in IL-6 (Table 5). Because HAP1 CAT is a “major”
haplotype (haplotype frequency > 0.50), 2 copies of
HAP1 were used as the reference group to be consistent
with the reference groups used for HAP2 and HAP3,
which are “minor” haplotypes (haplotype frequency <
0.50). Participants carrying 0 or 1 copies of major HAP1
CAT had a decreased risk of LOAD (AOR = 0.65, 95%
CI = 0.44-0.95) compared to those carrying 2 copies of
major HAP1.
Effect modification by vascular risk factors
Among the vascular risk factors explored in this study
(e.g., hypertension, type 2 DM, and hyperlipidemia),
hypertension was the only factor that significantly modi-
fied the association between IL-6 SNPs and risk of
LOAD (SNP2: pinteraction = 0.03 under dominant model,
Table 6). Hypertension history significantly decreased
the risk of LOAD (AOR = 0.41, 95% CI = 0.28-0.60,
Table 6). After stratification by hypertension status,
hypertensive patients carrying variant SNP2 had a
decreased risk of LOAD (AOR = 0.43, 95% CI = 0.22-
0.86, Table 6). Similar findings were observed for SNP1
and SNP3 (SNP1: AOR = 0.53, 95% CI = 0.29-0.96;
SNP3: AOR = 0.53, 95% CI = 0.29-0.97). After stratifica-
tion by type 2 DM, non-DM patients carrying variant
SNP1 and SNP3 were associated with a decreased
LOAD risk (AOR = 0.54 and 0.58, Table 6). The asso-
ciations above remained statistically significant after
controlling for FDR.
For IL-6 haplotypes, vascular risk factors or ApoE e4 sta-
tus did not significantly modify the association between
IL-6 haplotypes and the risk of LOAD (pinteraction > 0.05).
After stratification by hypertension history, hypertensive
Table 3 Characteristics of IL-6 haplotype-tagging SNPs and ApoE SNPs
HapMap or dbSNP This study
SNP name Nucleotide change Location rs no. MAF Controls Cases
CEU JPT CHB MAF HWE MAF HWE
c
2 p c
2 p
SNP1 C®G Promoter rs1800796 0.04 0.14 0.23 0.26 0.98 0.32 0.22 0.36 0.55
SNP2 A®G Intron rs2069837 0.08 0.10 0.17 0.19 2.59 0.11 0.16 0.04 0.84
SNP3 T®C Intron rs1524107 0.05 0.18 0.29 0.27 1.31 0.25 0.22 0.22 0.64
ApoE112 T®C Exon rs429358 0.15* 0.01 0.00 0.08 0.17 0.68 0.23 1.24 0.27
ApoE158 C®T Exon rs7412 0.08* 0.05 0.11 0.08 1.49 0.22 0.06 0.001 0.97
Abbreviations: CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; JPT, Japanese in Tokyo, Japan; CHB, Han Chinese in
Beijing; HWE p, p value for Hardy-Weinberg equilibrium test; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
The degree of freedom is 1 for all HWE tests.
* MAF data were obtained from dbSNP because the data was not available from the HapMap Project.
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of LOAD (AOR = 0.52, 95% CI = 0.29-0.95, Table 7). After
stratification by type 2 DM, non-DM patients carrying
minor HAP1 were associated with a decreased LOAD risk
(AOR = 0.59, 95% CI = 0.39-0.92, Table 7).
Discussion
In addition to replicating findings for rs1800796
explored in previous Asian studies [12-14], this study
for the first time identifies two IL-6 htSNPs (rs2069837
and rs1524107) representative for the Chinese popula-
tion, and rs1524107 showed a significant association
with LOAD. We found that a variant of SNP rs1800796
is significantly associated with decreased risk of LOAD,
which is consistent with the findings from a Chinese
study [12]. In addition, we found that the intronic SNP
rs1524107 and a haplotype CAT have a significant pro-
tective effect on LOAD risk, which has not been
reported previously. Unlike rs1800796 and rs1524107,
variant rs2068937 was not significantly associated with
LOAD (Table 4). Although they are located in one
block [i.e., highly linkage disequilibrium (LD) with dark
gray in Figure 1], rs2068937 shows a low correlation
with rs1800796 (r
2 = 0.58) and rs1524107 (r
2 =0 . 6 2 )
which explains its lack of a significant association with
LOAD.
rs1800796 is a promoter SNP, which may enhance
transcription efficiency [28] and affect plasma CRP
levels [29] and subsequent inflammatory responses.
These results indicate that the promoter SNP rs1800796
might be involved in the course of inflammation, and
the variant rs1800796 could alter IL-6 production in the
development of AD. Sequence variants of rs1524107
may affect disease risk via their effect on alternative spli-
cing, e.g., altering mRNA folding or the stability of
mRNA structure, and subsequent protein production.
Besides, the most common IL-6 haplotype CAT, com-
posed of three major alleles, was associated with
decreased risk of LOAD. Therefore, carrying 0 or 1
copies of CAT showed consistent protective effects on
LOAD risk, as did the variant IL-6 SNPs. These
sequence changes may either block or attenuate inflam-
mation signaling which leads to reduced risk of AD.
This supports the finding of a protective effect from IL-
Table 4 Association between IL-6 SNPs and LOAD risk by ApoE e4 status
Dominant model Additive model
0 copies 1 or 2 copies
Case/
control
AOR Case/
control
AOR (95% CI) p AOR (95% CI) p
SNP1 162/245 1.00 104/196 0.64 (0.43-0.94)* 0.02 0.67 (0.50-0.91)* 0.01
ApoE e4 non-carriers 100/207 1.00 61/166 0.56 (0.35-0.90)* 0.02 0.61 (0.42-0.90)* 0.01
ApoE e4 carriers 61/37 1.00 43/29 0.82 (0.40-1.70) 0.60 0.81 (0.49-1.34) 0.28
SNP2 180/293 1.00 75/141 0.78 (0.51-1.19) 0.25 0.80 (0.56-1.14) 0.21
ApoE e4 non-carriers 114/249 1.00 40/118 0.72 (0.43-1.20) 0.21 0.72 (0.46-1.12) 0.14
ApoE e4 carriers 66/43 1.00 35/22 0.89 (0.42-1.91) 0.77 0.99 (0.54-1.83) 0.59
SNP3 163/242 1.00 102/199 0.60 (0.41-0.89)* 0.01 0.66 (0.49-0.90)* < 0.01
ApoE e4 non-carriers 101/204 1.00 60/169 0.55 (0.35-0.88)* 0.01 0.60 (0.41-0.89)* 0.01
ApoE e4 carriers 61/37 1.00 42/29 0.73 (0.36-1.52) 0.40 0.81 (0.48-1.34) 0.23
All models were adjusted for age, gender, education, and ApoE e4 status.
Abbreviations: AOR, adjusted odds ratio; LOAD, late-onset Alzheimer’s disease; SNP, single nucleotide polymorphism.
* p value remained significant after controlling for type I error by using FDR.
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of IL-6 in LOAD is demonstrated in Figure 2.
Although ApoE e4 status is a well-known predictor for
AD risk, over half of AD cases (61% in this study, Table
2) do not carry the ApoE e4 allele. Therefore, prediction
of LOAD risk among ApoE e4 non-carriers becomes an
important task. This study found significant associations
between rs1800796 or rs1524107 and LOAD in ApoE e4
non-carriers, which remained statistically significant
after correction for type I error by using FDR. A Chi-
nese study [13] found that the variant rs1800796 was
associated with AD risk in ApoE e4 carriers but not in
t h ew i d e rp o p u l a t i o n .T h i sm a yb eac h a n c ef i n d i n g
because a significant protective effect of rs1800796 var-
iants on AD risk was observed only after stratification
by ApoE e4 status. In contrast, both He et al. [12] and
o u rs t u d yf o u n das i g n i f i c a n ta ssociation before stratifi-
cation. A previous study showed that elevated serum IL-
6 induces hypertriglyceridemia [30], which manifests
before the deposition of beta amyloid (Ab) in AD [31].
Therefore, IL-6 polymorphisms may be important in
predicting LOAD in ApoE e4 non-carriers.
Genotyping data from public domains (HapMap and
dbSNP) show that IL-6 and ApoE SNPs show geographic
variations (Table 3). MAFs of three IL-6 SNPs
(rs1800796, rs2069837, and rs1524107) are similar for
Table 5 Association between IL-6 haplotypes and LOAD
Prevalence in controls, % 2 copies 1 or 0 copies
Case/Control AOR Case/Control AOR (95% CI) p
HAP1 (CAT)
a 73.3 159/244 1.00 107/200 0.65 (0.44-0.95) 0.02
ApoE e4 non-carriers 99/206 1.00 62/170 0.57 (0.36-0.91) 0.02
ApoE e4 carriers 59/37 1.00 45/29 0.85 (0.42-1.76) 0.67
Prevalence in controls, % 0 copies 1 or 2 copies
Case/Control AOR Case/Control AOR (95% CI) p
HAP2 (GGC) 17.8 263/439 1.00 3/5 1.10 (0.16-7.58) 0.92
HAP3 (GAC) 8.1 260/442 1.00 6/2 2.56 (0.39-16.95) 0.33
a Two copies of HAP1 was used as the reference group because it is a “major” haplotype (haplotype frequency > 0.5).
Abbreviations: AOR, adjusted odds ratio; HAP, haplotype; LOAD, late-onset Alzheimer’s disease.
All models were adjusted for age, gender, education, and ApoE e4 status.
Table 6 Association between IL-6 SNPs and LOAD by
hypertension or type 2 DM
Dominant model pinteraction
a
0 copies 1 or 2 copies
Case/
Control
AOR Case/
Control
AOR (95% CI)
Hypertension 266/443 0.41 (0.28-0.60) NA
SNP1
No 96/105 1.00 69/98 0.64 (0.37-1.09) 0.54
Yes 66/139 1.00 35/98 0.53 (0.29-0.96)*
SNP2
No 106/131 1.00 52/67 1.09 (0.61-1.92) 0.03
Yes 74/161 1.00 23/74 0.43 (0.22-0.86)*
SNP3
No 99/102 1.00 66/100 0.59 (0.34-1.01) 0.74
Yes 64/139 1.00 36/99 0.53 (0.29-0.97)*
Type 2 DM 263/442 0.47 (0.30-0.74) NA
SNP1
No 136/210 1.00 81/167 0.58 (0.38-0.90)* 0.48
Yes 25/33 1.00 23/29 0.91 (0.36-1.31)
SNP2
No 146/251 1.00 61/119 0.77 (0.48-1.23) 0.96
Yes 33/40 1.00 14/22 0.78 (0.28-2.20)
SNP3
No 136/207 1.00 80/171 0.54 (0.35-0.84)* 0.39
Yes 26/33 1.00 22/28 0.92 (0.37-2.31)
a pinteraction value was obtained by using the dominant model.
All models were adjusted for age, gender, education, and ApoE e4 status.
Abbreviations: AOR, adjusted odds ratio; DM, diabetes mellitus; LOAD, late-
onset Alzheimer’s disease; SNP, single nucleotide polymorphism; NA, not
applicable.
* Result remained significant after controlling for type I error by using FDR.
Table 7 Association between IL-6 haplotype CAT and
LOAD by hypertension or type 2 DM
2 copies
a 0 or 1 copy pinteraction
b
Case/
Control
AOR Case/
Control
AOR
(95% CI)
Hypertension
No 94/104 1.00 71/100 0.67
(0.39-1.15)
0.49
Yes 65/139 1.00 36/100 0.52
(0.29-0.95)
Type 2 DM
No 133/209 1.00 84/171 0.59
(0.39-0.92)
0.36
Yes 25/33 1.00 23/29 0.91
(0.36-2.26)
Abbreviation: AOR, adjusted odds ratio; DM, diabetes mellitus; LOAD, late-
onset Alzheimer’s disease.
All models were adjusted for age, gender, education, and ApoE e4 status.
a 2 copies of haplotype CAT was used as the reference group because it is a
major haplotype.
b pinteraction value was obtained by using the dominant model.
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of the HapMap project (0.17-0.29). In comparison with
these two Chinese populations, for the same IL-6 SNPs,
Japanese populations have lower MAFs (0.10-0.18), and
the MAFs are even lower in Caucasians (0.04-0.08). For
ApoE SNPs, the MAF of AopE112 (rs429358) is highest
among Caucasians (dbSNP: 0.15), followed by controls
in this Chinese population (0.08), and by Japanese (0.01)
and CHB (0.00) from the HapMap Project. The incon-
sistency between the two Chinese populations for
ApoE112 may be attributable to the small number of
samples genotyped in HapMap study (n = 45 for CHB
and n = 43 for JPN). For ApoE158 (rs7412), the MAFs
were similar between Chinese (0.08-0.11) and Cauca-
sians (0.08) across ethnic groups with a lower value
observed in Japanese (0.05).
Hypertension significantly modified the association of
IL-6 SNPs with LOAD risk. The protective effect of
three IL-6 SNPs for LOAD was especially evident
among participants with hypertension (Table 6), which
may be a result of medication for treating hypertension
that can lower inflammatory responses (Figure 2). For
example, angiotensin receptor blockers or angiotensin-
converting enzyme inhibitors have been used to lower
blood pressure. Their accompanying neuroprotective
effects can reduce neuronal damage and lead to slowed
progression of AD [32,33]. Sequence variants of IL-6
may lower blood pressure, and subsequent brain hypo-
perfusion and neural degeneration, which eventually
decreases LOAD risk (Figure 2). However, experimental
studies are needed to clarify the underlying mechanism.
This study had some strengths. First, the htSNPs in IL-6
were identified to explore LOAD risk for the first time.
Second, the selection of two representative htSNPs cap-
tured abundant genetic information regarding the IL-6
gene (r
2 = 1.00) as compared to the genetic information
captured by the single promoter SNP (rs1800796, r
2 =
0.81) in previous candidate-gene studies [12,13]. Third,
the associations between IL-6 SNPs and LOAD risk
remained significant after correction for type I error using
FDR, which indicates that these findings are not chance
findings. In addition, high false positive rate in genome-
wide association studies prevent identifying SNPs asso-
ciated with disease outcome but with moderate p values in
t h ee x p l o r a t o r ys t a g e[ 3 4 ] .T his study, which selected
htSNPs that are representative for Chinese and captured
abundant genetic information for IL-6,m a ys o l v et h e
above issue. Furthermore, brain imaging was used to
exclude other diseases with similar presentation as LOAD.
Our study had some limitations. A self-report ques-
tionnaire was used to collect information on vascular
risk factors (e.g., hypertension, hyperlipidemia, and type
2 DM). Because these diseases/conditions are major
health issues, participants’ recall of disease/condition
diagnosis and their awareness of these diseases/condi-
tions tend to be relatively accurate [35-37]. Therefore,
information bias should not be a concern.
Conclusions
In addition to a significant association of rs1800796 with
LOAD, this study for the first time found that an IL-6
htSNP (rs1524107) and a haplotype CAT were signifi-
cantly associated with LOAD risk after correction for
multiple tests. These associations remained significant in
ApoE e4 non-carriers only. Because the majority of AD
patients are ApoE e4 non-carriers (61% in this study and
another Chinese study [13]), IL-6 SNPs may be impor-
tant markers in predicting LOAD risk in ApoE e4 non-
carriers. In addition, hypertension significantly modified
the association of IL-6 polymorphisms with LOAD risk.
Future large studies are warranted to explore the role of
IL-6 in risk of LOAD.
Abbreviations
Aβ: Beta amyloid; AD: Alzheimer’s disease; AOR: Adjusted odds ratio; ApoE:
Apolipoprotein; CHB: Han Chinese in Beijing China; CI: Confidence interval;
Figure 2 Postulated pathway of IL-6 and factors involved in the pathogenesis of dementia. Solid lines indicate pathways that have been
well documented; dotted lines indicated speculative pathways. Abbreviations: Ab, beta amyloid; IL-6R, interleukin 6 receptor; ARBs, angiotensin
receptor blockers; AECIs, angiotensin-converting enzyme inhibitors; ApoE e4, apolipoprotein E e4; AD, Alzheimer’s disease.
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HAP: Haplotype; htSNPs: Haplotype-tagging SNPs; HWE: Hardy-Weinberg
equilibrium; LD: Linkage disequilibrium; LOAD: Late-onset Alzheimer’s
disease; MAF: Minor allele frequency; SNP: Single nucleotide polymorphism.
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